Sarepta Therapeutics Inc (NASDAQ:SRPT) Director M Kathleen Behrens purchased 2,500 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were bought at an average price of $87.98 per share, for a total transaction of $219,950.00. Following the completion of the transaction, the director now directly owns 123,167 shares in the company, valued at approximately $10,836,232.66. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of SRPT stock traded down $3.32 during mid-day trading on Friday, hitting $85.70. 1,331,337 shares of the stock traded hands, compared to its average volume of 2,249,680. Sarepta Therapeutics Inc has a twelve month low of $85.23 and a twelve month high of $165.87. The firm has a market cap of $6.62 billion, a price-to-earnings ratio of -15.70 and a beta of 2.19. The company’s 50-day simple moving average is $121.93 and its 200-day simple moving average is $127.03. The company has a debt-to-equity ratio of 0.44, a quick ratio of 7.84 and a current ratio of 8.81.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative net margin of 165.52% and a negative return on equity of 55.37%. The firm had revenue of $94.67 million for the quarter, compared to analyst estimates of $91.05 million. During the same quarter last year, the business posted ($1.67) earnings per share. The firm’s revenue for the quarter was up 28.8% compared to the same quarter last year. Analysts forecast that Sarepta Therapeutics Inc will post -4.94 earnings per share for the current year.

A number of analysts have recently weighed in on the company. Credit Suisse Group dropped their price target on Sarepta Therapeutics from $207.00 to $201.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 20th. Evercore ISI restated a “buy” rating and issued a $200.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, August 8th. Bank of America lowered their target price on Sarepta Therapeutics from $200.00 to $189.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Piper Jaffray Companies lowered their target price on Sarepta Therapeutics from $208.00 to $185.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 20th. Finally, Robert W. Baird lowered their target price on Sarepta Therapeutics from $202.00 to $181.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. Sarepta Therapeutics has a consensus rating of “Buy” and an average target price of $197.78.

Hedge funds have recently modified their holdings of the company. Evolution Wealth Advisors LLC acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at $25,000. Trust Co. of Vermont increased its position in shares of Sarepta Therapeutics by 2,125.0% during the 2nd quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 170 shares during the period. Steward Partners Investment Advisory LLC acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at $32,000. BSW Wealth Partners acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at $52,000. Finally, Coastal Investment Advisors Inc. increased its position in shares of Sarepta Therapeutics by 57.4% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 425 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 155 shares during the period. Institutional investors own 93.59% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Story: How Investors Can Profit from Options Trading

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.